Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CES 2022: Abbott CEO Robert Ford Announces New Biowearables Line For Consumers, Paving The Way From Measuring Glucose To Ketone, Lactate, Alcohol

Executive Summary

Abbott announced today at CES 2022 it is developing a new line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year. 

You may also be interested in...

Abbott’s Metabolic Health Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing

Lingo, based on Abbott’s FreeStyle Libre diabetes management technology but targeted to the consumer market, works with a companion app to identify user habits that negatively impact their health and guide them in modifying behaviors accordingly. Olivier Ropars, division VP of Lingo Biowearables, discusses the company's recent UK launch and future plans.

Abbott’s Metabolic Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing

Medtech Insight caught up with Abbott’s division VP of Lingo Biowearables at HLTH to learn more about its recent UK launch and future plans.

Abbott’s Lingo Biowearable For Consumers Debuts In The UK As Libre Momentum Continues

Abbott launched its first biowearable for consumers in the UK with plans to expand in Europe and the US. Analysts are optimistic about continued growth of Libre FreeStyle amid drivers such as CGM adoption by non-insulin users, expected 15-day sensor, streaming capability and integration with Tandem insulin pump.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts